Correspondence 0001193125-26-129018 from Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc.
Date: March 27, 2026 · CIK: 0001645460 · Accession: 0001193125-26-129018
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294366
Letter
Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed March 16, 2026 File No. 333-294366 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cue Biopharma, Inc. (the “ Registrant ”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-294366), so that it may become effective at 4:00 p.m. Eastern time on March 31, 2026, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the Staff.
CUE BIOPHARMA, INC. 40 Guest Street Boston, Massachusetts 02135 March 27, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller
Very truly yours,
CUE BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP CUE BIOPHARMA, INC. 40 Guest Street Boston, Massachusetts 02135 March 27, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance, Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Cue Biopharma, Inc. Registration Statement on Form S-3 Filed March 16, 2026 File No. 333-294366 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cue Biopharma, Inc. (the “ Registrant ”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-294366), so that it may become effective at 4:00 p.m. Eastern time on March 31, 2026, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the Staff. Very truly yours, CUE BIOPHARMA, INC. By: /s/ Lucinda Warren Name: Lucinda Warren Title: Interim President and Chief Executive Officer